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Available online 25 May 2016Objective: Preeclampsia (preE) has a signiﬁcant link to alterations of placental function leading to stress and ap-
optotic signaling, which pass the placental barrier and leave persistent defect in the circulation of the offspring.
We assessed apoptotic signaling in placentas and umbilical cords from patients with and without preE.
Methods:We collected placental and cord tissues from 27 normal pregnant (NP) women and 20 preE consenting
patients after delivery in an IRB approved prospective study. p38 mitogen-activated protein kinase (p38MAPK)
phosphorylation, pro-apoptotic Bcl-2-associated X (Bax), anti-apoptotic Bcl-2, caspase-9, and pro-inﬂammatory
cyclooxygenase-2 (Cox-2) were evaluated by western blot and immunohistochemistry. Comparisons were per-
formed using Student's t-test.
Results: p38 phosphorylation (Placenta: 1.5 fold, Cord: 1.7 fold), ratio of Bax/Bcl-2 (Placenta: 1.7 fold, Cord: 2.2
fold), caspase-9 (Placenta: 1.5 fold, Cord: 1.8 fold) and Cox-2 (Placenta: 2.5 fold, Cord: 2.3 fold) were up-
regulated (p b 0.05) in preE compared to NP patients. Average hospital stays for preE babies were longer than
NPbabies. No complicationswere reported for NPbabies; however, all of preE babies hadmultiple complications.
Conclusions: Apoptotic and stress signaling are augmented in preE placenta and cord tissue that alter the intra-
uterine environment and activates the detrimental signaling that is transported to fetus.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Preeclampsia1. Introduction
Preeclampsia (preE), is a clinical syndrome characterized by a systol-
ic blood pressure (BP) of ≥140 mm Hg or a diastolic BP of ≥90 mm Hg
accompanied by proteinuria of ≥0.3 g in a 24-hour urine sample that be-
gins after 20weeks gestation [1–4]. Its prevalence rate is 3 to 8% world-
wide and it is one of the leading causes of maternal and fetal morbidity
and mortality [1–4]. The mechanism of preE is extensively being stud-
ied; however the reason why preE occurs is elusive. Several theories
point to abnormal placentation caused by hypoxic insults and oxidative
stress leading to placental apoptosis is being pursued [1–4]. The placen-
ta in turn releases vasculotoxic substances which passes the placental
barrier and goes to the circulation of the offspring that may predispose
to a pathological response to the fetus, upon birth or later in life [1–4].lding 1) Room 352, 2401 South
. This is an open access article underTheories proposed to cause preeclampsia include angiogenic imbal-
ance [2,5,6], autoantibodies to angiotensin type 1 (AT1) receptor [7,8],
cardiotonic steroids [9–11], genetic predisposition [3] and immunological
factors [12]. The angiogenic imbalance is the effect of vascular endothelial
growth factor (VEGF) on the proliferation and survival of endothelial
cells. It has a vasodilator effect on the systemic vessels that increases vas-
cular permeability [2,3,5,12]. However, it was found that there is an in-
creased sensitivity to elevated levels of circulating angiotensin receptor
AT1 activating antibody that may lead to preE [7,8]. The cardiotonic ste-
roids particularly Marinobufagenin (MBG) from the bufodienolide
group has the ability to inhibit the Na+/K+ ATPase, increase plasma
MBG promotes volume expansion and hypertension [3,9–11]. MBG has
also been shown to alter the proliferation and migration of specialized
cytotrophoblasts (CTBs) in the placenta thereby decreases the perfusion
of the feto-maternal unit resulting in oxidative stress and endothelial dys-
function [9–11,13].MBGplays amajor role in the pathogenesis of preE in-
cluding activation of apoptotic signaling and alteration of endothelial cell
growth [3,11,14].
preE can occur through two connected pathways placental tropho-
blast dysfunction and endothelial dysfunction within the maternalthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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the placenta such as vasoconstricting agents and altered cytokines can
cause greater oxidative stress leading to endothelial dysfunction [15].
This refers to the fact that several endothelial cells did not show the
proper response to speciﬁc stimuli in preE women. One study by Gant
et al. found vascular resistance produced in response to increases in
levels of angiotensin II was lost in preE patients [16,17]. Possible culprit
factors for endothelial dysfunction include Platelet-activating factor and
P-selectin, which when unregulated favored increased platelet activity
and endothelial retraction [18,19]. Once a preE pregnancy is terminated
however, disturbances in maternal circulation dissolve rapidly due to
elimination of these placental factors [19]. Indeed, when endothelial
dysfunction is combined with pre-existing conditions such as vascular,
renal, and metabolic diseases and other genetic factors, there is a
much greater risk for developing preE.While placental pathophysiology
is not the primary pathway for developing preE, it is an important con-
tributor in the development of the disorder during pregnancy.
In this prospective study, we assessed the apoptotic and stress sig-
naling proteins in the placenta and umbilical cord of normal pregnant
and preE patients The outcomes of the pregnancy were also been
followed. The purpose of the study is to correlate the presence of stress
and apoptotic signaling markers in the placenta and umbilical cord and
their relationship to the outcome in the offspring.
2. Methods and materials
2.1. Human subjects
In this study, we recruited 20 pregnant women who present with
preeclampsia deﬁned as BP ≥ 140/90 with proteinuria of N300 mg of
protein in a 24 hours urine sample and 27 pregnant women with un-
complicated pregnancy as control from the department of Obstetrics
and Gynecology at Baylor Scott & White Hospital in Temple Texas. The
hospital's Institutional Review Board approved the study and informed
consentwas granted by the subjects. The clinical status and assessments
at the time of admission for maternal symptoms andmaternal age were
taken. The infants' weight, length, gestational age, length of hospitaliza-
tion and associatedmorbidities were recorded. Samples of placenta and
umbilical cord were collected from the recruited subjects after delivery.
The p38 MAPK phosphorylation was evaluated by Western blot.
Apoptotic markers; Bcl-2 associated X protein (Bax), pro-apoptotic
Bcl-2 protein, caspase-9 and pro-inﬂammatory protein cyclo-
oxygenase-2 (Cox-2) expression were assayed both by Western
blot and immunohistochemistry.
2.2. Western blot analysis for p38 MAPK, Bax, Bcl-2, caspase-9 and Cox-2
proteins
Placenta and umbilical cordwere homogenizedwith a cell lysis buff-
er (Cell Signaling Technology) containing 0.1 M Tris at pH 7.4, 50 M
NaCl, 0.5 M EDTA at pH 8, Igepal andwater and protease inhibitor cock-
tail. Protein concentrations were determined by BCA reagent (Pierce,
Rockford, IL). An equal amount of protein in each sample was separated
using NuPage Novex 4–12% Bis-Tris gels (Invitrogen) and transferred to
nitrocellulose membranes. Membranes were blocked in 5%milk probed
with anti-p38 MAPK, Bax, Bcl-2, caspase-9 and Cox-2 antibodies. After
incubation with the corresponding secondary antibody, proteins were
visualized with chemiluminescence detection system (Pierce). The in-
tensity of the bands was determined using ImageQuant LAS 4000 (GE
Healthcare Life Sciences). The expression of p38 MAPK, Bax, Bcl-2,
caspase-9 and Cox-2 was quantiﬁed by densitometry analysis using
Image J software where the target protein is normalized to a structural
protein (β-actin) to control between groups and ensures correction
for the amount of total protein on the membrane. The phospho-p38
was normalized to total p38.2.3. Immunohistochemistry (IHC) of placenta and umbilical cord samples
from preE and NP patients
Placenta and umbilical cord samples were frozen in Optimal Cutting
Temperature (OCT) compound and cut on the Cryostat as 20 micron
thick slices. Tissue slices were put on positively charged slides. Slides
were incubated at 37 °C for 15min andwashed in PBS (phosphate buff-
ered saline) for 5min. Slideswere places in 0.01%hydrogen peroxide for
20min andwashed in PBS for 5min. A hydrophobic penwas used to cir-
cle tissue sections and 5% goat serum was added to the circled tissue
sections for 2 h. Slides were placed in a humidiﬁed box and the Anti-
Bax, Bcl-2, caspase-9 and Cox-2 antibodies (Abcam) were added in 1%
goat serum. Negative control samples were placed in the humidiﬁed
box without the antibody and only 1% goat serum. The humidiﬁed box
was placed in the refrigerator overnight. Slides were washed in PBS
three times for 30 min. The secondary antibody was added in 1% goat
serum to slides for 2 h. Then slides were again washed in PBS three
times for 30 min. Diaminobenzidine was added to the slides for less
than 30 s then washed in water. Slides were then dipped 10 times in
50% alcohol, 70% alcohol, 90% alcohol, 95% alcohol, and xylene consecu-
tively. Finally, dibutyl phthalate xylene mountant was added to the
slides and a coverslip was placed over the tissue.
2.4. Statistical methods
Heterogeneity of variance of patient characteristics and assay values
were examined with Levene's test. For those measurements with het-
erogeneous variance,Mann-WhitneyU testswere used for comparisons
of the two patient groups. Otherwise, Student's t-tests were used to
compare groups. Data from the NP patients were compared to preE pa-
tients using Student's t-test. A p-value of less than 0.05 was considered
signiﬁcant.
3. Results
3.1. Human data
There was no signiﬁcant difference between the normal pregnant
and preE patients in terms of maternal age, maternal height and mean
gestational age at birth. As expected, pregnant patients with symptoms
of preE differed from thosewith normal pregnancies in variables related
to these symptoms. The mean systolic BP for the preE patients (166 ±
11 mm Hg) differed from the normal patients (122 ± 10 mm Hg) re-
spectively (p b 0.0001). The mean diastolic BP differed were 93 ± 10
and 74 ± 9 mm Hg, respectively (p 0.0001). The mean urinary protein
levels differed was 1974 ± 1149 mg/24 h in the preE group and
149.0 ± 56.6 mg/24 h in the NP group (p = 0.0001). We did not ﬁnd
any difference in body mass index (BMI) between NP (30.6 ± 6.9
(27)) and preE women (34.2 ± 7.8 (20)), p = 0.095. Patients with NP
were about 4 weeks further along in pregnancy than those with preE
pregnancies, but the range of gestations for both groups was 28 to
39 weeks of gestation (Table 1).
We divided the preE subjects into early (before 34 weeks) and late
preE (after 34 weeks) groups and compared their outcomes. The placen-
tal thickness in early preE subjectswas 25mmcompared to 32mm in late
preE (p = 0.05) and placental volume in early preE 296 cm3 compared
to 393 cm3 (p = 0.0498). Gestational age at delivery in early preE is
32.4 weeks vs 36.8 weeks in late preE (p = 0.011). About 56% of the in-
fants (5 out of 9) who are born to early preE are small for gestational
age (SGA) and 30% of the infants (3 out of 10) who are born to late preE
are SGA (Fig. 1). Qualitative demographic variables are shown in Table 2.
3.2. WB data for p38 MAPK, Bax, Bcl-2, caspase-9 and Cox-2 proteins
The p38 MAPK phosphorylation in both the placenta and umbilical
cord was upregulated in preE patients compared to control (*p b 0.05)
Table 1
Quantitative demographic variables (means ± SD (n)).
Variables Patients with
preeclampsia
Normal
pregnancies
p-Value
Parity 2.1 ± 2.4 (20) 2.4 ± 1.5 (27) 0.11b
Maternal age (yrs) at delivery 28.8 ± 6.4 (20) 28.2 ± 4.4 (27) 0.74a
Maternal weight (pounds) 204 ± 50 (20) 177 ± 44 (27) 0.046b
Maternal height (inches) 65 ± 5 (20) 64 ± 3 (27) 0.69b
Maternal BMI (kg/m2) 34.2 ± 7.8 (20) 30.6 ± 6.9 (27) 0.095a
Systolic blood pressure
(mm Hg)
166 ± 11 (20) 122 ± 10 (27) b0.0001a
Diastolic blood pressure
(mm Hg)
93 ± 10 (20) 74 ± 9 (27) b0.0001a
Urinary protein (mg/24 h) 1974 ± 1149(20) 105 ± 17 (27) b0.0001b
Gestational age at delivery
(weeks)
34.8 ± 4.0 (20) 39.2 ± 0.3 (27) b0.0001b
Baby weight (grams) 2287 ± 872 (20) 3528 ± 354 b0.0001b
Rohrer's ponderal index 2.46 ± 0.32 (20) 2.94 ± 0.25 (27) b0.0001a
Infant length of stay (days) 20 ± 26 (20) 2 ± 0.5 (27) b0.0001b
a Comparison using Student's t-test.
b Comparison using Mann-Whitney U test.
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cord compared to normal (*p b 0.05 (Fig. 3 a–b). The expression of apo-
ptotic signaling protein caspase-9 was higher in preE placenta and um-
bilical cord compared to NP (Fig. 4a–b). The Cox-2 expression was
upregulated in placental and cord samples of preE patients compared
to control (*p b 0.05 (Fig. 5a–b). We followed up the babies for both
groups of patients after delivery for two weeks to assess the immediate
pregnancy outcome.
3.3. Pregnancy outcomes
preE babieswere stayed signiﬁcantly longer period of time in hospital
compared to NP babies (~3 vs ~26 days) after delivery for treatment of
multiple complications. There were no complications in 6 infants, who
are born to preE mothers. The complications of preE babies were as fol-
lows: 7 had hypoglycemia; 1 had hyperbilirubinemia; 7 had respiratory
distress syndrome; 2 had bronchopulmonary dysplasia; 8 had intrauter-
ine growth restriction; 6 had thrombocytopenia; 1 of each had retinopa-
thy of prematurity (ROP), intraventricular hemorrhage (IVH) andFig. 1. preE subjects are divided into early preE (before 34weeks) and late preE (after 34weeks
25mmcompared to 32mm in late preE (p=0.05) andplacental volume in early preE296 cm3 c
36.8weeks in late preE (p=0.011). About 56% of the infants (5 out of 9)who are born to early p
late preE are SGA.hypoxic ischemic encephalopathy (HIE). However, so far there were no
complications observed among the NP babies.
4. Discussion
The apoptotic and stress signaling proteins were signiﬁcantly up-
regulated in preE placentas and umbilical cords compared to normal
pregnancies. The pregnancy outcomes for the preE pregnancies were
complicated compared to normal pregnancies. Reduced blood supply
leading to hypoxia from reduced uterine perfusion (RUPP) appears to
be a signiﬁcant pathophysiologic mechanism leading to preE. The feto-
placental unit reacts by producing a cascade of inﬂammatory mediators
and anti-angiogenic factors [20,21]. The proposed mechanisms of re-
duced uterine perfusion and hypoxia, elevated antiangiogenic factors
and systemic endothelial dysfunction are the signiﬁcant pathophysiologic
mechanism leading to the development of preE, and the higher BPs lead
to increased stroke and atherogenesis [4,20,21]. RUPP seems to be one of
the key determinants leading to hypoxia. The feto-placenta unit reacts by
producing reactive oxygen species and cytokines, inducing a cascade of
inﬂammatorymediators and anti-angiogenic factors [4,20,21]. This theo-
ry has been replicated in animal models. The timing of fetal exposure to
preE is critical. Studies have demonstrated an increase in BP in RUPP an-
imals compared with controls, whereas exposure to the effects of in-
creased BP in late gestation indicate no difference in BP in the offspring
compared to controls [22]. Placental hypoxia has been suggested as a con-
tributing factor for the development of preE, in animal studies that surgi-
cally induced uteroplacental ischemia causes hypertension, proteinuria,
and elevated levels of circulating sFlt-1 [23]. Hypoxic conditions have ac-
tually shown an increased invasiveness of CTBs, indicating that the pri-
mary malfunction must be abnormal placentation resulting in placental
hypoxia [12,13,15].
The explanation of the pathogenetic mechanism of how preE causes
the many deleterious effects in offspring has been studied extensively.
A comprehensive analysis by Davis et al. showed that there is a
2.4 mm Hg increase in systolic BP in childhood and young adult life
which is associated with an 8% increased risk of mortality from ischemic
heart disease and a 12% increase risk from stroke [24,25]. Preterm infants
born to preEmothers also had lower ﬂow-mediated dilatation which is a
marker of endothelial dysfunction [26]. Endothelial dysfunction is an) groups and compared their outcomes. The placental thickness in early preE subjects was
ompared to 393 cm3 (p=0.0498). Gestational age at delivery in early preE is 32.4weeks vs
reE are small for gestational age (SGA) and 30% of the infants (3 out of 10)who are born to
Fig. 2. (a) The p38 MAPK phosphorylation was measured in the placental tissue from two
groups of patients by Western blotting, running the homogenate from the placental tissues
from NP and preE patients in gel followed by detecting with immunoblotting using anti-
phospho-p38/anti-total-p38 antibodies. The patients were: normal pregnant (NP, n = 15)
and preeclamptic (preE, n = 15). The placental p38 MAPK phosphorylation was
signiﬁcantly upregulated in preE patients compared to NP (*p b 0.05). The results
presented are the mean ± SE. A blot from a representative experiment is shown in the
ﬁgure. (b) The p38 MAPK phosphorylation was measured in the umbilical cord tissue from
two groups of patients by Western blotting, running the homogenate from the cord tissues
from NP and preE patients in gel followed by detecting with immunoblotting using anti-
phospho-p38/anti-total-p38 antibodies. The patients were: normal pregnant (NP, n = 15)
and preeclamptic (preE, n = 15). The cord p38 MAPK phosphorylation was signiﬁcantly
upregulated in preE patients compared to NP (*p b 0.05). The results presented are the
mean ± SE. A blot from a representative experiment is shown in the ﬁgure.
Fig. 3. Representative blots of BAX/BCL-2 and beta-actin in placental (a) and umbilical
cord (b) tissues from two groups of patients: NP (n = 15) and preE (n = 15). Graph
presents means with SE of 15 experiments of each group for the expression of BAX/BCL-
2 relative to beta-actin in the tissue lysates of (a) placental and (b) umbilical cord by
Western Blot. The BAX/BCL-2 was signiﬁcantly upregulated both in placenta and cord
tissues of preE patients compared to NP (*p b 0.05). The results presented are the
mean ± SE.
28 S.H. Afroze et al. / BBA Clinical 6 (2016) 25–30important indicator for subsequent cardiovascular disease and is present
in preE [25,27]. preE infants had higher BP and thicker carotid intima as a
young adult. These can either be due to genetic predisposition or in utero
exposure to inﬂammation, represented by the increased number of in-
ﬂammatory markers in offspring of preE mothers [28]. preE mothers
were found to have increased circulating levels of inﬂammatorymarkers,
which correlates to the development of the syndrome [5,26].
Shaker and Sadik [29] shown that increased oxidative stress in preE
leads to lipid peroxidation results in elevation of Malondialdehyde
(MDA, a marker of lipid peroxidation). They have also demonstrated in-
creased caspase-9 activity and DNA fragmentation in preE secondary to
increased oxidative stress. Zhang et al. [30] have reported AP-2α depen-
dent regulation of Bcl-2/Baxmodulates the apoptosis in trophoblast cells.
They have shown that there is increased apoptosis in trophoblast cells in
preE secondary to overexpression of AP-2α leading to imbalance be-
tween anti-apoptotic Bcl-2 and pro-apoptotic Bax signaling molecules
resulting in preE. Mudgett et al. [31] have demonstrated the role of p38
MAPK in placental, embryonic and yolk sac angiogenesis. They have hy-
pothesized that activation of p38MAPK is required for the angiogenic re-
sponse to the relative hypoxic state during early placentation. Websteret al. [32] have found that increased nitration of p38 MAPK decreases
p38 MAPK activity resulting in poor placentation and preE development.
Goksu Erol et al. [33] have demonstrated the roles of decreased iNOS ex-
pression and increased Cox-2 expression in decreased placental blood
ﬂow and increased resistance to the ﬂow in the feto-maternal circulation
resulting preE. Cawyer et al. have proven the hyperglycemia induced
cytotrophoblast dysfunction and increased expression of p38 MAPK
phosphorylation, PPARγ, Bcl-2-associated-X protein (Bax) and anti-
apoptotic Bcl-2 ratio, caspase-9, and cyclooxygenase-2 (Cox-2) [34]. All
of the above mentioned investigators had worked on different stress
and apoptotic signaling molecules individually. In our experiment, we
demonstrated expression of multiple signaling molecules like p38
MAPK, Bcl-2/Bax, caspase-9 and Cox-2 in preE and normal placental
and cord tissues explaining their role in pathogenesis of preE.
preE is associatedwith endothelial dysfunction in themother, which
is related to the release of circulating vasculotoxic factors and the induc-
tion of augmented oxidative stress by the diseased placenta [6,22,25,27,
28,35]. These circulating factorsmay pass theplacental barrier and leave
persistent defects in the circulation of the offspring thatmay predispose
to a pathological response later in life. Jayet et al. showed someevidence
of vascular dysfunction in young offspring of mothers with preE [35]. It
was found that pulmonary artery pressure is roughly 30% higher in off-
spring of mothers with preE than control subjects [35]. They also noted
that brachial artery ﬂowmediated dilatation is 30% lower in offspring of
mothers with preE. The vascular dysfunction was related to preE itself
Fig. 4. (a) Caspase-9 was measured in the placental tissue from NP and preE patients by
immunoblotting using anti-caspase antibody. The patients were: normal pregnant (NP,
n = 15) and preeclamptic (preE, n = 15). The placental caspase-9 was signiﬁcantly
upregulated in preE patients compared to NP (*p b 0.05). The results presented are the
mean ± SE. A blot from a representative experiment is shown in the ﬁgure. (b) Caspase-9
was measured in the cord tissue from NP and preE patients by immunoblotting using anti-
caspase-9 antibody. The patients were: normal pregnant (NP, n = 15) and preeclamptic
(preE, n = 15). The cord caspase-9 was signiﬁcantly upregulated in preE patients
compared to NP (*p b 0.05). The results presented are the mean ± SE. A blot from a
representative experiment is shown in the ﬁgure.
Fig. 5. Representative blots of Cox-2 and beta-actin in placental (a) and umbilical cord
(b) tissues from two groups of patients: NP (n = 15) and preE (n = 15). Graph
presents means with SE of 15 experiments (each group) for the expression of Cox-2
relative to beta-actin in the tissue lysates of (A) placental and (B) umbilical cord by
immunoblotting using anti-Cox-2 antibody. Cox-2 was signiﬁcantly upregulated both in
placenta and cord tissues of preE patients compared to NP (*p b 0.05). The results
presented are the mean ± SE.
Table 2
Qualitative demographic variables (proportions (%)).
Variables Patients with
preeclampsia
Normal
pregnancies
p-Valuea
Mode of delivery
Cesarean delivery/total 12/20 (60%)b 24/27 (89%)b 0.021
Baby gender
Male/total 8/20 (40%) 12/27 (44%) 0.76
Infant complications
Yes/total 14/20 (70%)c 4/27 (15%)c 0.001
Infant size at delivered less
than 10th percentile for
gestational age (IUGR)
Yes/total 8/20 (40%) 2/27 (7%) 0.007
Required NICU care
Yes/total 13/20 (65%) 2/27 (7%) b0.0001
a Comparison using chi-square test.
b Need to list indications for cesarean sections for both groups with N for each
indication.
c Complications for infants of the two study groups.
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a normal pregnancy had normal vascular function [35].
According to a study done by Hakim et al., the rate of very early pre-
term delivery (less than 32 weeks of pregnancy) was 21.2% in uncom-
plicated preE and 37.2% in preE complicated by with prior chronic
hypertension [22], illustrating the detrimental effect of hypertension
alone on gestational age. Established preE serves as the basis for 15%
of all preterm births [22]. Diseases of prematurity affecting every vital
organ system have a higher frequency in the offspring of preE mothers
due to the increased incidence of prematurity in this cohort. Neurolog-
ically, intraventricular hemorrhage and retinopathy of prematurity
occur soon after birth more frequently in babies born to preE mothers;
intellectual disabilities, hearing disabilities, and cerebral palsy plague
these infants long-term [36]. Respiratory issues such as prolonged
ventilator-dependence and bronchopulmonary dysplasia tied to devel-
opmental immaturity have been shown to occurmore often in these in-
fants in prospective studies [25]. Necrotizing enterocolitis, the most
common gastrointestinal emergency of infants, occurs more frequently
in this group in preE offspring [25,37,38].
The increased apoptotic signaling in preEwhichmay lead to reduced
nutrient transport capacity triggering placental release of vascular fac-
tors that producematernal vascular responses characteristic of this syn-
drome. preE modiﬁes the intrauterine environment by altering thepattern of hormonal signals and activating the detrimental cellular sig-
naling that has been transported to the fetus. The fetus has to adapt to
the change in intrauterine milieu and this adaptation increases the
risk of disease to the offspring. Further prospective and retrospective
studies with human subjects are ongoing by our research group to un-
derstand the mechanism of the transmission of detrimental signaling
30 S.H. Afroze et al. / BBA Clinical 6 (2016) 25–30from mothers to the offspring. The stress and detrimental cellular sig-
naling molecules that have been overexpressed in the placental and
cord tissues from preE patients raises the possibility that those signals
could be therapeutically blocked one day.
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